


Claim Amendments

1(original). A compound of Formula (I)



wherein

X is carbon and Y is nitrogen, or X is nitrogen and Y is carbon;

R¹ is a lone pair of electrons, hydrogen, (C₁-C₆)alkyl, or (C₃-C₆)cycloalkyl;

R² is hydrogen, (C₁-C₆)alkyl, or (C₃-C₆)cycloalkyl;


R³ is hydrogen or a chemical moiety selected from the group consisting of (C₁-C₆)alkyl, 2- to 8-membered carbocyclic ring, 5- to 6-membered heterocyclic ring, aryl, 5- to 9-membered heteroaryl, (C₁-C₆)alkylaryl, (C₁-C₆)alkylheteroaryl, and aryloxy(C₁-C₆)alkyl when X is carbon or nitrogen, where said chemical moiety is optionally substituted, or

R³ is a lone pair of electrons when X is nitrogen;

R⁴ is hydrogen or a chemical moiety selected from the group consisting of (C₁-C₆)alkyl, aryl, or aryl(C₁-C₆)alkyl when Y is carbon or nitrogen, where said chemical moiety is optionally substituted, or

R⁴ is a lone pair of electrons when Y is nitrogen; and

Q is a group selected from



where Z in each occurrence is independently nitrogen or CR⁷, R⁵ is an optionally substituted aryl or an optionally substituted heteroaryl, R⁶ is an optionally substituted

aryl or an optionally substituted heteroaryl, and R^7 is hydrogen, halo, cyano, or (C_1-C_6) alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(original). The compound of Claim 1 where R^5 and R^6 are each independently an aryl or a heteroaryl, where said aryl and said heteroaryl are substituted with one to three substituents selected from the group consisting of halo, (C_1-C_4) alkoxy, (C_1-C_4) alkyl, halo-substituted (C_1-C_4) alkyl and cyano.

3(original). The compound of Claim 2 wherein R^5 is 2,4-dihalophenyl or 2-halophenyl and R^6 is 4-halophenyl or 2- (C_1-C_6) alkoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

4(original). The compound of Claim 3 wherein R^5 is 2,4-dichlorophenyl or 2-chlorophenyl and R^6 is 4-chlorophenyl or 2-methoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5(original). The compound of Claim 1 selected from the group consisting of
5-(4-chloro-phenyl)-3-(5-cyclohexyl-1H-imidazol-2-yl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole;

5-(4-chloro-phenyl)-3-(2-cyclohexyl-3H-imidazol-4-yl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole;

5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole;

5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-4-methyl-3-[1-(1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole;

5-(4-chloro-phenyl)-1-(2-fluoro-phenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole;



5-(4-chloro-phenyl)-1-(2-chloro-phenyl)-3-[1-(2,2-dimethyl-tetrahydro-pyran-4-yl)-1H-imidazol-4-yl]-4-methyl-1H-pyrazole:

5-{2-(2,4-dichloro-phenyl)-4-methyl-5-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-2H-pyrazol-3-yl}-2-methoxy-pyridine; and

1-(2-chloro-phenyl)-5-(4-chloro-phenyl)-4-methyl-3-[1-(1-methyl-1-phenyl-ethyl)-1H-imidazol-4-yl]-1H-pyrazole;

a pharmaceutically acceptable salt thereof or a solvate or hydrate of said compound or said salt.

6(original). A compound having Formula (IA) or (IB)



wherein

R¹ and R² are each independently hydrogen, (C₁-C₆)alkyl, or (C₃-C₆)cycloalkyl;

R³ is hydrogen or a chemical moiety selected from the group consisting of (C₁-C₆)alkyl, 2- to 8-membered carbocyclic ring, 5- to 6-membered heterocyclic ring, aryl, 5- to 9-membered heteroaryl, (C₁-C₆)alkylaryl, (C₁-C₆)alkylheteroaryl, and aryloxy(C₁-C₆)alkyl, where said chemical moiety is optionally substituted;

R⁴ is hydrogen or a chemical moiety selected from the group consisting of (C₁-C₆)alkyl, aryl, and aryl(C₁-C₆)alkyl, where said chemical moiety is optionally substituted;

R⁵ is an optionally substituted aryl or an optionally substituted heteroaryl;

R⁶ is an optionally substituted aryl or an optionally substituted heteroaryl; and


R⁷ is hydrogen, halo, cyano, or (C₁-C₆)alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7(original). The compound of Claim 6 where R^5 and R^6 are each independently an aryl or a heteroaryl, where said aryl and said heteroaryl are substituted with one to three substituents selected from the group consisting of halo, (C_1-C_4) alkoxy, (C_1-C_4) alkyl, halo-substituted (C_1-C_4) alkyl and cyano.

8(original). The compound of Claim 7 having Formula (IA); a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9(original). A compound having Formula (IC) or (ID)



wherein

R^1 and R^2 are each independently hydrogen, (C_1-C_6) alkyl, or (C_3-C_6) cycloalkyl;

R^3 is hydrogen or a chemical moiety selected from the group consisting of (C_1-C_6) alkyl, 2- to 8-membered carbocyclic ring, 5- to 6-membered heterocyclic ring, aryl, 5- to 9-membered heteroaryl, (C_1-C_6) alkylaryl, (C_1-C_6) alkylheteroaryl, and aryloxy (C_1-C_6) alkyl, where said chemical moiety is optionally substituted;

R^4 is hydrogen or a chemical moiety selected from the group consisting of (C_1-C_6) alkyl, aryl, and aryl (C_1-C_6) alkyl, where said chemical moiety is optionally substituted;

R^5 is an optionally substituted aryl, or an optionally substituted heteroaryl;

R^6 is an optionally substituted aryl, or an optionally substituted heteroaryl; and

R^7 is hydrogen, halo, cyano, or (C_1-C_6) alkyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

10(original). The compound of Claim 9 where R^5 and R^6 are each independently an aryl or a heteroaryl, where said aryl and said heteroaryl are substituted with one to three substituents selected from the group consisting of halo, (C_1-C_4) alkoxy, (C_1-C_4) alkyl, halo-substituted (C_1-C_4) alkyl and cyano.

11(original). The compound of Claim 7, 8, or 10 wherein R^5 is 2,4-dihalophenyl or 2-halophenyl and R^6 is 4-halophenyl or 2- (C_1-C_6) alkoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

12(original). The compound of Claim 11 wherein R^5 is 2,4-dichlorophenyl or 2-chlorophenyl and R^6 is 4-chlorophenyl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

13(original). A pharmaceutical composition comprising (1) a compound of Claim 1, a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

14(original). The pharmaceutical composition of Claim 13 wherein said compound of Claim 1 is a compound where R^5 is 2,4-dichlorophenyl or 2-chlorophenyl and R^6 is 4-chlorophenyl or 2-methoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

15(original). The pharmaceutical composition of Claim 13 or 14 further comprising a nicotine partial agonist, an opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent.

16(original). The composition of Claim 15 wherein said anti-obesity agent is selected from the group consisting of an apo-B/MTP inhibitor, an 11 β -hydroxy steroid dehydrogenase-1 inhibitor, peptide YY₃₋₃₆ or an analog thereof, a MCR-4 agonist, a CCK-A agonist, a monoamine reuptake inhibitor, a sympathomimetic agent, a β_3 adrenergic receptor agonist, a dopamine agonist, a melanocyte-stimulating hormone receptor analog, a 5-HT_{2c} receptor agonist, a melanin concentrating hormone antagonist, leptin, a leptin analog, a leptin receptor agonist, a galanin antagonist, a lipase inhibitor, a bombesin agonist, a neuropeptide-Y receptor antagonist, a thyromimetic agent, dehydroepiandrosterone or analog thereof, a glucocorticoid receptor antagonist, an orexin receptor antagonist, a glucagon-like peptide-1 receptor agonist, a ciliary neurotrophic factor, a human agouti-related protein antagonist, a ghrelin receptor antagonist, a histamine 3 receptor antagonist or inverse agonist, and a neuromedin U receptor agonist.

17(original). A pharmaceutical composition comprising (1) a compound of Claim 6, a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

18(original). The pharmaceutical composition of Claim 17 wherein said compound of Claim 6 is a compound where R⁵ is 2,4-dichlorophenyl or 2-chlorophenyl and R⁶ is 4-chlorophenyl or 2-methoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

19(original). The pharmaceutical composition of Claim 17 or 18 further comprising a nicotine partial agonist, opioid antagonist, a dopaminergic agent, an attention deficit disorder agent, or an anti-obesity agent .

20(original). The composition of Claim 19 wherein said anti-obesity agent is selected from the group consisting of an apo-B/MTP inhibitor, an 11 β -hydroxy steroid dehydrogenase-1 inhibitor, peptide YY₃₋₃₆ or an analog thereof, a MCR-4 agonist, a CCK-A agonist, a monoamine reuptake inhibitor, a sympathomimetic agent, a β_3 adrenergic receptor agonist, a dopamine agonist, a melanocyte-stimulating hormone receptor analog, a 5-HT_{2c} receptor agonist, a melanin concentrating hormone antagonist, leptin, a leptin analog, a leptin receptor agonist, a galanin antagonist, a lipase inhibitor, a bombesin agonist, a neuropeptide-Y receptor antagonist, a thyromimetic agent, dehydroepiandrosterone or analog thereof, a glucocorticoid receptor antagonist, an orexin receptor antagonist, a glucagon-like peptide-1 receptor agonist, a ciliary neurotrophic factor, a human agouti-related protein antagonist, a ghrelin receptor antagonist, a histamine 3 receptor antagonist or inverse agonist, and a neuromedin U receptor agonist.

21(currently amended). A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1, a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug, wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is selected from the group consisting of eating disorders, weight loss or control, obesity, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, substance abuse, addictive disorders, impulsivity, alcoholism, tobacco abuse, dementia, sexual dysfunction in males, seizure disorders, epilepsy, gastrointestinal disorders, attention deficit disorder, Parkinson's disease, and type II diabetes.

22(currently amended). The method of ~~Claim 18~~ Claim 21 wherein said compound of Claim 1 is a compound where R⁵ is 2,4-dichlorophenyl or 2-chlorophenyl and R⁶ is 4-chlorophenyl or 2-methoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

23(cancelled).

24(currently amended). The method of ~~Claim 23~~ Claim 22 wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is obesity, alcoholism, attention deficit disorder, or tobacco abuse.

25-26(cancelled).

27(currently amended). A method for treating a disease, condition or disorder modulated by a cannabinoid receptor antagonist in animals comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 6, a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug, wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is selected from the group consisting of eating disorders, weight loss or control, obesity, depression, atypical depression, bipolar disorders, psychoses, schizophrenia, behavioral addictions, suppression of reward-related behaviors, substance abuse, addictive disorders, impulsivity, alcoholism, tobacco abuse, dementia, sexual dysfunction in males, seizure disorders, epilepsy, gastrointestinal disorders, attention deficit disorder, Parkinson's disease, and type II diabetes.

28(original). The method of Claim 27 wherein said compound of Claim 6 is a compound where R⁵ is 2,4-dichlorophenyl or 2-chlorophenyl and R⁶ is 4-chlorophenyl or 2-methoxypyridin-5-yl;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

29(cancelled).

30(currently amended). The method of ~~Claim 29~~ Claim 28 wherein said disease, condition or disorder modulated by a cannabinoid receptor antagonist is obesity, alcoholism, attention deficit disorder, or tobacco abuse.

31-32(cancelled).